- Home
- RIG vs RYTM Comparison
RIG vs RYTM Comparison
Compare RIG & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIG
- RYTM
- Stock Information
- Founded
- RIG 1926
- RYTM 2008
- Country
- RIG Switzerland
- RYTM United States
- Employees
- RIG N/A
- RYTM N/A
- Industry
- RIG Oil & Gas Production
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- RIG Energy
- RYTM Health Care
- Exchange
- RIG Nasdaq
- RYTM Nasdaq
- Market Cap
- RIG 3.6B
- RYTM 3.5B
- IPO Year
- RIG 1993
- RYTM 2017
- Fundamental
- Price
- RIG $3.90
- RYTM $60.40
- Analyst Decision
- RIG Hold
- RYTM Strong Buy
- Analyst Count
- RIG 10
- RYTM 10
- Target Price
- RIG $5.56
- RYTM $66.90
- AVG Volume (30 Days)
- RIG 25.8M
- RYTM 494.9K
- Earning Date
- RIG 02-17-2025
- RYTM 02-20-2025
- Dividend Yield
- RIG N/A
- RYTM N/A
- EPS Growth
- RIG N/A
- RYTM N/A
- EPS
- RIG N/A
- RYTM N/A
- Revenue
- RIG $3,313,000,000.00
- RYTM $112,530,000.00
- Revenue This Year
- RIG $26.06
- RYTM $65.99
- Revenue Next Year
- RIG $9.72
- RYTM $45.07
- P/E Ratio
- RIG N/A
- RYTM N/A
- Revenue Growth
- RIG 22.84
- RYTM 81.55
- 52 Week Low
- RIG $3.40
- RYTM $35.17
- 52 Week High
- RIG $6.88
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- RIG 48.27
- RYTM 60.20
- Support Level
- RIG $3.72
- RYTM $57.67
- Resistance Level
- RIG $4.04
- RYTM $60.69
- Average True Range (ATR)
- RIG 0.16
- RYTM 2.10
- MACD
- RIG -0.01
- RYTM 0.41
- Stochastic Oscillator
- RIG 30.00
- RYTM 90.79
About RIG Transocean Ltd (Switzerland)
Transocean Ltd. is an international provider of offshore contract drilling services for oil and gas wells. Its segment involves contracting mobile offshore drilling rigs, related equipment, and work crews to drill oil and gas wells.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.